These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


584 related items for PubMed ID: 16907872

  • 1. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
    Furuya K, Murai K, Yokoyama T, Maeno H, Takeda Y, Murozuka T, Wakisaka A, Tanifuji M, Tomono T.
    Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
    [Abstract] [Full Text] [Related]

  • 2. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
    Chtourou S, Porte P, Nogré M, Bihoreau N, Cheesman E, Samor B, Sauger A, Raut S, Mazurier C.
    Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
    [Abstract] [Full Text] [Related]

  • 3. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate).
    Stadler M, Gruber G, Kannicht C, Biesert L, Radomski KU, Suhartono H, Pock K, Neisser-Svae A, Weinberger J, Römisch J, Svae TE.
    Biologicals; 2006 Dec; 34(4):281-8. PubMed ID: 16500114
    [Abstract] [Full Text] [Related]

  • 4. Removal of small non-enveloped viruses by nanofiltration.
    Yokoyama T, Murai K, Murozuka T, Wakisaka A, Tanifuji M, Fujii N, Tomono T.
    Vox Sang; 2004 May; 86(4):225-9. PubMed ID: 15144526
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.
    Soluk L, Price H, Sinclair C, Atalla-Mikhail D, Genereux M.
    Am J Ther; 2008 May; 15(5):435-43. PubMed ID: 18806519
    [Abstract] [Full Text] [Related]

  • 12. In vitro study of a triple-secured von Willebrand factor concentrate.
    Mazurier C, Poulle M, Samor B, Hilbert L, Chtourou S.
    Vox Sang; 2004 Feb; 86(2):100-4. PubMed ID: 15023178
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII.
    Roberts PL, Dunkerley C, McAuley A, Winkelman L.
    Vox Sang; 2007 Jan; 92(1):56-63. PubMed ID: 17181591
    [Abstract] [Full Text] [Related]

  • 17. Pathogen safety of Beriate®.
    Gröner A.
    Thromb Res; 2014 Nov; 134 Suppl 1():S10-5. PubMed ID: 24726555
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 30.